This finding is not consistent with the present understanding of the hypoxia-HIF1-STAT3-TMZ sensitivity axis and might thus relativize current efforts to develop specific STAT3 inhibitors to improve efficacy of glioblastoma management [30]. This evidence concerns the gene HIF1A and glioblastoma.